Failed degradation of JunB contributes to overproduction of type i collagen and development of dermal fibrosis in patients with systemic sclerosis

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 243-253

  Ponticos, Markella ^a   Papaioannou, Ioannis ^a   Xu, Shiwen ^a   Holmes, Alan M ^a   Khan, Korsa ^a   Denton, Christopher P ^a   Bou Gharios, George ^b   Abraham, David J ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; GLYCOGEN SYNTHASE KINASE 3BETA; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR COL1A2; TRANSCRIPTION FACTOR FRA 1; TRANSCRIPTION FACTOR FRA 2; TRANSCRIPTION FACTOR JUNB; TRANSCRIPTION FACTOR JUND; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ALPHA 2(I) COLLAGEN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; JUNB PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DISEASE COURSE; GEL MOBILITY SHIFT ASSAY; GENE ACTIVATION; GENE CONSTRUCT; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; PATHOGENESIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REPORTER GENE; RNA INTERFERENCE; SKIN BIOPSY; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TRANSIENT TRANSFECTION; BIOPSY; CASE CONTROL STUDY; CELL CULTURE; FIBROSIS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SKIN;

BIOPSY; CASE-CONTROL STUDIES; CELLS, CULTURED; COLLAGEN TYPE I; FIBROSIS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; PROTO-ONCOGENE PROTEINS C-AKT; SCLERODERMA, SYSTEMIC; SIGNAL TRANSDUCTION; SKIN; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION FACTORS;

EID: 84919913137     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38897     Document Type: Article

References (31)

1. De Val S, Ponticos M, Antoniv TT, Wells DJ, Abraham D, Partridge T, et al. Identification of the key regions within the mouse pro-α2(I) collagen gene far-upstream enhancer. J Biol Chem 2002; 277: 9286-92.
2. Antoniv TT, De Val S, Wells D, Denton CP, Rabe C, de Crombrugghe B, et al. Characterization of an evolutionarily conserved far-upstream enhancer in the human α2(I) collagen (COL1A2) gene. J Biol Chem 2001; 276: 21754-64.
3. Tanaka S, Antoniv TT, Liu K, Wang L, Wells DJ, Ramirez F, et al. Cooperativity between far upstream enhancer and proximal promoter elements of the human α2(I) collagen (COL1A2) gene instructs tissue specificity in transgenic mice. J Biol Chem 2004; 279: 56024-31.
4. De Crombrugghe B, Vuorio T, Karsenty G, Maity S, Rutheshouser EC, Goldberg H,. Transcriptional control mechanisms for the expression of type I collagen genes. Ann Rheum Dis 1991; 50 Suppl 4: 872-6.
5. Ponticos M, Abraham D, Alexakis C, Lu QL, Black C, Partridge T, et al. Col1a2 enhancer regulates collagen activity during development and in adult tissue repair. Matrix Biol 2004; 22: 619-28.
6. Ponticos M, Harvey C, Ikeda T, Abraham D, Bou-Gharios G,. JunB mediates enhancer/promoter activity of COL1A2 following TGF-β induction. Nucleic Acids Res 2009; 37: 5378-89.
7. Angel P, Karin M,. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-57.
8. Angel P, Szabowski A, Schorpp-Kistner M,. Function and regulation of AP-1 subunits in skin physiology and pathology. Oncogene 2001; 20: 2413-23.
9. Angel P, Szabowski A,. Function of AP-1 target genes in mesenchymal-epithelial cross-talk in skin. Biochem Pharmacol 2002; 64: 949-56.
10. Brenner DA, O'Hara M, Angel P, Chojkier M, Karin M,. Prolonged activation of jun and collagenase genes by tumour necrosis factor-α. Nature 1989; 337: 661-3.
11. George SJ, Lloyd CT, Angelini GD, Newby AC, Baker AH,. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296-304.
12. Verrecchia F, Tacheau C, Schorpp-Kistner M, Angel P, Mauviel A,. Induction of the AP-1 members c-Jun and JunB by TGF-β/Smad suppresses early Smad-driven gene activation. Oncogene 2001; 20: 2205-11.
13. Gurzov EN, Bakiri L, Alfaro JM, Wagner EF, Izquierdo M,. Targeting c-Jun and JunB proteins as potential anticancer cell therapy. Oncogene 2008; 27: 641-52.
14. Schonthaler HB, Guinea-Viniegra J, Wagner EF,. Targeting inflammation by modulating the Jun/AP-1 pathway. Ann Rheum Dis 2011; 70 Suppl 1: i109-12.
15. Schreiber M, Kolbus A, Piu F, Szabowski A, Mohle-Steinlein U, Tian J, et al. Control of cell cycle progression by c-Jun is p53 dependent. Genes Dev 1999; 13: 607-19.
16. Verrecchia F, Wagner EF, Mauviel A,. Distinct involvement of the Jun-N-terminal kinase and NF-κB pathways in the repression of the human COL1A2 gene by TNF-α. EMBO Rep 2002; 3: 1069-74.
17. Avouac J, Palumbo K, Tomcik M, Zerr P, Dees C, Horn A, et al. Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. Arthritis Rheum 2012; 64: 1642-52.
18. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, et al. The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis. Ann Rheum Dis 2011; 70: 1320-6.
19. Reich N, Tomcik M, Zerr P, Lang V, Dees C, Avouac J, et al. Jun N-terminal kinase as a potential molecular target for prevention and treatment of dermal fibrosis. Ann Rheum Dis 2012; 71: 737-45.
20. Reich N, Maurer B, Akhmetshina A, Venalis P, Dees C, Zerr P, et al. The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. Arthritis Rheum 2010; 62: 280-90.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
22. BXW7 targets JunB for degradation in G2 to preserve chromatid cohesion before anaphase. Oncogene 2013; 32: 2189-99.
23. Gao M, Labuda T, Xia Y, Gallagher E, Fang D, Liu YC, et al. Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase Itch. Science 2004; 306: 271-5.
24. Maurer B, Reich N, Juengel A, Kriegsmann J, Gay RE, Schett G, et al. Fra-2 transgenic mice as a novel model of pulmonary hypertension associated with systemic sclerosis. Ann Rheum Dis 2012; 71: 1382-7.
25. Mao X, Orchard G, Lillington DM, Child FJ, Vonderheid EC, Nowell PC, et al. BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004; 151: 546-56.
26. Bossy-Wetzel E, Bravo R, Hanahan D,. Transcription factors junB and c-jun are selectively up-regulated and functionally implicated in fibrosarcoma development. Genes Dev 1992; 6: 2340-51.
27. Gao M, Karin M,. Regulating the regulators: control of protein ubiquitination and ubiquitin-like modifications by extracellular stimuli. Mol Cell 2005; 19: 581-93.
28. Perez-Benavente B, Farras R,. Regulation of GSK3β-FBXW7-JUNB axis. Oncotarget 2013; 4: 956-7.
29. Shegogue D, Trojanowska M,. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem 2004; 279: 23166-75.
30. Yoshizaki A, Yanaba K, Yoshizaki A, Iwata Y, Komura K, Ogawa F, et al. Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum 2010; 62: 2476-87.
31. Su TI, Khanna D, Furst DE, Danovitch G, Burger C, Maranian P, et al. Rapamycin versus methotrexate in early diffuse systemic sclerosis: results from a randomized, single-blind pilot study. Arthritis Rheum 2009; 60: 3821-30.